The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Discovery and Development of SQ109: A New Antitubercular Drug with a Novel Mechanism of Action
Open accessAbstract
Existing drugs have limited efficacy against the rising threat of drug-resistant TB, have significant side effects, and must be given in combinations of four to six drugs for at least 6 months for drug-sensitive TB and up to 24 months for drug-resistant TB. The long treatment duration has led to increased patient noncompliance with therapy. This, in turn, drives the development of additional drug resistance in a spiral that has resulted in some forms of TB being currently untreatable by existing drugs. New antitubercular drugs in development, particularly those with mechanisms of action that are different from existing first- and second-line TB drugs, are anticipated to be effective against both drug-sensitive and drug-resistant TB. SQ109 is a new TB drug candidate with a novel mechanism of action that was safe and well tolerated in Phase I and early Phase II clinical trials. We describe herein the identification, development and characterization of SQ109 as a promising new antitubercular drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
Small, P. M., Hopewell, P. C., Singh, S. P., Paz, A., Parsonnet, J., Ruston, D. C., Schecter, G. F., Daley, C. L., & Schoolnik, G. K. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406163302402 · Cited by 1,111
Gandhi, N. R., Nunn, P., Dheda, K., Schaaf, H. S., Zignol, M., van Soolingen, D., Jensen, P., & Bayona, J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60410-2 · Cited by 1,018
Armstrong, J. A., & Hart, P. D. (1971) · The Journal of Experimental Medicine · doi:10.1084/jem.134.3.713 · Cited by 990
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Diacon, A. H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808427 · Cited by 835
Self-citationMetronidazole Is Still the Drug of Choice for Treatment of Anaerobic Infections
Löfmark, S., Edlund, C., & Nord, C. E. (2010) · Clinical Infectious Diseases · doi:10.1086/647939 · Cited by 656
Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Van Deun, A., Maug, A. K. J., Salim, M. A. H., Das, P. K., Sarker, M. R., Daru, P., & Rieder, H. L. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0077oc · Cited by 647
The Transcriptional Responses of Mycobacterium tuberculosis to Inhibitors of Metabolism
Boshoff, H. I. M., Myers, T. G., Copp, B. R., McNeil, M. R., Wilson, M. A., & Barry, C. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406796200 · Cited by 606
Self-citationThe Effect of Directly Observed Therapy on the Rates of Drug Resistance and Relapse in Tuberculosis
Weis, S. E., Slocum, P. C., Blais, F. X., King, B., Nunn, M., Matney, G. B., Gomez, E., & Foresman, B. H. (1994) · New England Journal of Medicine · doi:10.1056/nejm199404283301702 · Cited by 589
Orenstein, E. W., Basu, S., Shah, N. S., Andrews, J. R., Friedland, G. H., Moll, A. P., Gandhi, N. R., & Galvani, A. P. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70041-6 · Cited by 540
Tahlan, K., Wilson, R., Kastrinsky, D. B., Arora, K., Nair, V., Fischer, E., Barnes, S. W., Walker, J. R., Alland, D., Barry, C. E., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05708-11 · Cited by 504
Self-citationHIV Infection and Multidrug‐Resistant Tuberculosis—The Perfect Storm
Wells, C. D., Cegielski, J. P., Nelson, L. J., Laserson, K. F., Holtz, T. H., Finlay, A., Castro, K. G., & Weyer, K. (2007) · The Journal of Infectious Diseases · doi:10.1086/518665 · Cited by 483
Belanger, A. E., Besra, G. S., Ford, M. E., Mikusová, K., Belisle, J. T., Brennan, P. J., & Inamine, J. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11919 · Cited by 466
Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane
Grzegorzewicz, A. E., Pham, H., Gundi, V. A. K. B., Scherman, M. S., North, E. J., Hess, T., Jones, V., Gruppo, V., Born, S. E. M., Korduláková, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.794 · Cited by 442
Dormancy ofMycobacterium tuberculosis and latency of disease
Wayne, L. G. (1994) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf02111491 · Cited by 387
Protopopova, M., Hanrahan, C., Nikonenko, B., Samala, R., Chen, P., Gearhart, J., Einck, L., & Nacy, C. A. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki319 · Cited by 371
Self-citationInhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis
Takayama, K., & Kilburn, J. O. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.9.1493 · Cited by 369
Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence
Stevenson, C. R., Forouhi, N. G., Roglic, G., Williams, B. G., Lauer, J. A., Dye, C., & Unwin, N. (2007) · BMC Public Health · doi:10.1186/1471-2458-7-234 · Cited by 365
Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations
Sreevatsan, S., Stockbauer, K. E., Pan, X., Kreiswirth, B. N., Moghazeh, S. L., Jacobs, W. R., Telenti, A., & Musser, J. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.8.1677 · Cited by 335
Rustomjee, R., Diacon, A. H., Allen, J., Venter, A., Reddy, C., Patientia, R. F., Mthiyane, T. C. P., De Marez, T., van Heeswijk, R., Kerstens, R., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01204-07 · Cited by 278
The oxazolidinones: past, present, and future
Shaw, K. J., & Barbachyn, M. R. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06330.x · Cited by 259
Activities of Several Novel Oxazolidinones against Mycobacterium tuberculosis in a Murine Model
Cynamon, M. H., Klemens, S. P., Sharpe, C. A., & Chase, S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1189 · Cited by 243
Pharmacodynamics and pharmacokinetics of SQ109, a new diamine‐based antitubercular drug
Jia, L., Tomaszewski, J. E., Hanrahan, C., Coward, L., Noker, P., Gorman, G., Nikonenko, B., & Protopopova, M. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705984 · Cited by 231
Self-citationLee, R. E., Protopopova, M., Crooks, E., Slayden, R. A., Terrot, M., & Barry, C. E. (2003) · Journal of Combinatorial Chemistry · doi:10.1021/cc020071p · Cited by 207
Self-citationLinezolid, the first oxazolidinone antibacterial agent
Leach, K. L., Brickner, S. J., Noe, M. C., & Miller, P. F. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05962.x · Cited by 195
Epidemiology and clinical management of XDR-TB: a systematic review by TBNET
Sotgiu, G., Ferrara, G., Matteelli, A., Richardson, M. D., Centis, R., Ruesch-Gerdes, S., Toungoussova, O., Zellweger, J.-P., Spanevello, A., Cirillo, D., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00168008 · Cited by 180
Drug-Resistant Tuberculosis—Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs
Zumla, A., Abubakar, I., Raviglione, M., Hoelscher, M., Ditiu, L., Mchugh, T. D., Squire, S. B., Cox, H., Ford, N., McNerney, R., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir858 · Cited by 175
Alland, D., Steyn, A. J., Weisbrod, T., Aldrich, K., & Jacobs, W. R. (2000) · Journal of Bacteriology · doi:10.1128/jb.182.7.1802-1811.2000 · Cited by 165
Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis
Dietze, R., Hadad, D. J., McGee, B., Molino, L. P. D., Maciel, E. L. N., Peloquin, C. A., Johnson, D. F., Debanne, S. M., Eisenach, K., Boom, W. H., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200806-892oc · Cited by 165
Chen, P. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl227 · Cited by 164
The Arabinosyltransferase EmbC Is Inhibited by Ethambutol in Mycobacterium tuberculosis
Goude, R., Amin, A. G., Chatterjee, D., & Parish, T. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00162-09 · Cited by 157
Nikonenko, B. V., Protopopova, M. N., Samala, R., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01326-06 · Cited by 143
Self-citationEfficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)—a report of ten cases
von der Lippe, B., Sandven, P., & Brubakk, O. (2005) · Journal of Infection · doi:10.1016/j.jinf.2005.04.007 · Cited by 142
In Vitro Interactions between New Antitubercular Drug Candidates SQ109 and TMC207
Reddy, V. M., Einck, L., Andries, K., & Nacy, C. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01601-09 · Cited by 134
Self-citationEthambutol dosage for the treatment of children: literature review and recommendations.
Donald, P. R., Maher, D., Maritz, J. S., & Qazi, S. (2006) · PubMed · Cited by 121
Current Status and Research Strategies in Tuberculosis Drug Development
Dover, L. G., & Coxon, G. D. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200305q · Cited by 120
Wallis, R. S., Jakubiec, W., Kumar, V., Silvia, A. M., Paige, D., Dimitrova, D., Li, X., Ladutko, L., Campbell, S. M., Friedland, G. H., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/655471 · Cited by 105
Drugs in Development for Tuberculosis
Ginsberg, A. M. (2010) · Drugs · doi:10.2165/11538170-000000000-00000 · Cited by 104
Interspecies pharmacokinetics and in vitro metabolism of SQ109
Jia, L., Noker, P. E., Coward, L. C., et al. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706650 · Cited by 102
Metronidazole Therapy in Mice Infected with Tuberculosis
Brooks, J. V., Furney, S. K., & Orme, I. M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1285 · Cited by 92
Klinkenberg, L. G., Sutherland, L., Bishai, W. R., & Karakousis, P. C. (2008) · The Journal of Infectious Diseases · doi:10.1086/589515 · Cited by 89
Plinke, C. F., Cox, H. S., Заркуа, Н. Э., Karimovich, H. A., Braker, K., Diel, R., Rüsch–Gerdes, S., Feuerriegel, S., & Niemann, S. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq120 · Cited by 89
Wallis, R. S., Jakubiec, W., Mitton‐Fry, M. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030479 · Cited by 72
Ansiedade e depressão em pacientes com asma: impacto no controle da asma
Vieira, A. A., Santoro, I. L., Dracoulakis, S., Caetano, L. B., & Fernandes, A. L. G. (2011) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132011000100004 · Cited by 71
Identification of SQ609 as a lead compound from a library of dipiperidines
Bogatcheva, E., Hanrahan, C. F., Nikonenko, B. V., Santos, G. D. L., Reddy, V., Chen, P., Barbosa, F., Einck, L., Nacy, C. A., & Protopopova, M. N. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.07.015 · Cited by 62
Self-citationRapid, Simple In Vivo Screen for New Drugs Active against Mycobacterium tuberculosis
Nikonenko, B. V., Samala, R., Einck, L., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4550-4555.2004 · Cited by 61
Metronidazole has no antibacterial effect in Cornell model murine tuberculosis.
Dhillon, J., Allen, B. W., Hu, Y., Coates, A. R. M., & Mitchison, D. A. (1998) · PubMed · Cited by 57
New Antituberculous Drugs in Development
Lalloo, U., & Ambaram, A. (2010) · Current HIV/AIDS Reports · doi:10.1007/s11904-010-0054-4 · Cited by 53
Tuberculosis Drugs: New Candidates and How to Find More
Sala, C., & Hartkoorn, R. C. (2011) · Future Microbiology · doi:10.2217/fmb.11.46 · Cited by 48
Jia, L., Coward, L. C., Gorman, G. S., Noker, P. E., & Tomaszewski, J. E. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087817 · Cited by 48
SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro
Reddy, V. M., Dubuisson, T., Einck, L., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr589 · Cited by 43
Jia, L., Tomaszewski, J. E., Noker, P. E., Gorman, G. S., Glaze, E. R., & Protopopova, M. N. (2004) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2004.11.036 · Cited by 33
Self-citationSynthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents
Meng, Q., Luo, H., Liu, Y., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.091 · Cited by 28
Vieira, A. A., & Ribeiro, S. A. (2011) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132011000200013 · Cited by 20
Cited by
Drug Resistance Mechanisms in Mycobacterium tuberculosis
Palomino, J., & Martin, A. (2014) · Antibiotics · doi:10.3390/antibiotics3030317 · Cited by 442
Boeree, M. J., Heinrich, N., Aarnoutse, R., Diacon, A. H., Dawson, R., Rehal, S., Kibiki, G. S., Churchyard, G., Sanne, I., Ntinginya, N. E., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30274-2 · Cited by 379
Alvin, A., Miller, K. I., & Neilan, B. A. (2014) · Microbiological Research · doi:10.1016/j.micres.2013.12.009 · Cited by 373
Prospects for new antibiotics: a molecule-centered perspective
Walsh, C. T., & Wencewicz, T. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2013.49 · Cited by 372
Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets
Alsayed, S. S. R., & Gunosewoyo, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065202 · Cited by 332
Metadata
- Authors
- Sacksteder, K. A., Protopopova, M., Barry, C. E., Andries, K., & Nacy, C. A.
- Venue
- Future Microbiology
- Publisher
- Informa UK Limited
- Published
- 2012-07
- Volume
- 7
- Issue
- 7
- Pages
- 823-837
- ISSN
- 1746-0913 (ISSN-L)
- 1746-0921
- OpenAlex
- W2125456670
- Cited by
- 269
- References
- 54
- FWCI
- 10.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.